Tirzepatide vs Mounjaro for weight loss explained: they're the same drug under different brand names. Compare approvals, doses, results, and cost.
Tirzepatide and Mounjaro are the same drug. Mounjaro is the brand name Eli Lilly uses for tirzepatide when it is prescribed for type 2 diabetes, and Zepbound is the brand name for the identical molecule when it is prescribed for weight loss. So the real question behind "tirzepatide vs Mounjaro for weight loss" is which product, dose, and FDA-approved indication you are actually comparing.
Tirzepatide Is the Ingredient, Mounjaro Is the Label
Tirzepatide is a once-weekly injection that activates two gut hormone receptors: GIP and GLP-1. That dual action slows stomach emptying and reduces appetite, which is why it produces noticeable weight loss even in people taking it for blood sugar control.
Mounjaro received FDA approval in May 2022 for adults with type 2 diabetes. Weight loss on Mounjaro is a well-documented effect, but it is not the indication the drug was approved for, which is exactly why so many people compare tirzepatide vs mounjaro and assume they are two different medications.
Zepbound was cleared by the FDA in November 2023 for chronic weight management in adults with obesity, or with overweight plus at least one weight-related condition such as high blood pressure, high cholesterol, or obstructive sleep apnea.
Mounjaro and Zepbound contain the exact same active ingredient: tirzepatide.
Mounjaro vs Zepbound vs Compounded Tirzepatide
The table below shows how the main tirzepatide products on the US market differ.
| Product | Active ingredient | FDA-approved use | Starting dose | Maximum dose |
|---|---|---|---|---|
| Mounjaro | Tirzepatide | Type 2 diabetes | 2.5 mg weekly | 15 mg weekly |
| Zepbound | Tirzepatide | Chronic weight management | 2.5 mg weekly | 15 mg weekly |
| Compounded tirzepatide | Tirzepatide (not an FDA-approved copy) | None | Varies by pharmacy | Varies by pharmacy |
Dosing is identical between Mounjaro and Zepbound: 2.5 mg once weekly for four weeks, then 5 mg, with step-ups roughly every four weeks as tolerated up to 15 mg weekly.
How Much Weight Do People Actually Lose?
In the SURMOUNT-1 trial, adults without diabetes who took 15 mg of tirzepatide weekly lost an average of about 21% of their starting body weight over 72 weeks. Participants on 5 mg lost roughly 15% on average.
For comparison, semaglutide 2.4 mg (Wegovy) produced about 15% average weight loss at 68 weeks in the STEP 1 trial. That difference is why so many people search tirzepatide vs semaglutide which is better for weight loss, though individual results vary widely and no single trial has compared every dose head to head.
Separate large trials show greater average weight loss with tirzepatide than with semaglutide, but response differs from person to person.
Does a Higher Tirzepatide Dose Mean More Weight Loss?
Generally yes, with diminishing returns. In SURMOUNT-1, average weight loss climbed at each dose step from 5 mg to 10 mg to 15 mg. When people ask do higher doses of tirzepatide increase weight loss, the trial data confirms the trend is real, but the extra benefit between 10 mg and 15 mg is smaller than the jump from 5 mg to 10 mg.
Higher doses also bring more gastrointestinal side effects. The most common complaints are:
- Nausea
- Vomiting
- Diarrhea or constipation
- Abdominal pain and reduced appetite
- Injection site reactions
Moving up in dose faster does not mean faster results — it usually means more side effects and a higher chance of stopping treatment.
Is Compounded Tirzepatide a Safe Option?
Compounded tirzepatide is not FDA-approved, and the FDA removed tirzepatide from its drug shortage list in late 2024, which sharply limits when a compounding pharmacy may legally prepare it. Independent testing has also found that some compounded samples contained more or less drug than the label stated.
If you are wondering is tirz safe for weight loss, the honest answer is that brand-name tirzepatide has a large safety database behind it and compounded versions do not. Both carry the same boxed warning about thyroid C-cell tumors observed in rodents, and both are contraindicated for people with a personal or family history of medullary thyroid cancer or MEN2.
Cost, Insurance, and Access
List prices for Mounjaro and Zepbound sit near $1,000 to $1,100 per month before insurance. Zepbound is far more likely to be covered for weight loss because that is its approved indication, while Mounjaro is usually covered only for type 2 diabetes.
Eli Lilly sells single-dose vials of Zepbound directly to cash-paying patients at lower prices than the auto-injector pen, and both drugs offer savings cards for commercially insured patients. Medicare Part D does not cover medications prescribed solely for weight loss.
Which One Should You Ask Your Doctor About?
If your goal is weight loss and you do not have type 2 diabetes, Zepbound is the tirzepatide product with the matching FDA indication. If you have type 2 diabetes, Mounjaro may be the right fit, and any weight loss on it is an added benefit rather than the approved purpose.
Either way, this is a prescription decision. Talk with a healthcare professional about your medical history, other medications, and how you would manage side effects before starting treatment.
Frequently Asked Questions
Is Mounjaro the same as tirzepatide?
Yes. Mounjaro is a brand name for tirzepatide, the active ingredient. The same molecule is sold as Zepbound for chronic weight management and as Mounjaro for type 2 diabetes. Both are once-weekly injections with identical dosing schedules.
Is Mounjaro or Zepbound better for weight loss?
They contain the same drug at the same doses, so the weight loss effect is the same. The difference is the FDA-approved indication: Zepbound is approved for chronic weight management, while Mounjaro is approved only for type 2 diabetes. Insurance coverage usually follows that distinction.
How much weight can you lose on tirzepatide?
In the SURMOUNT-1 trial, adults without diabetes lost an average of about 21% of their body weight on the 15 mg weekly dose over 72 weeks. The 5 mg dose produced roughly 15% average weight loss. Individual results depend on dose, diet, activity, and how long treatment continues.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.